Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bf3457b8e1b2c4047a2b6fb88283d74c2> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bf3457b8e1b2c4047a2b6fb88283d74c2 NCIT_P378 "NCI" @default.
- Bf3457b8e1b2c4047a2b6fb88283d74c2 type Axiom @default.
- Bf3457b8e1b2c4047a2b6fb88283d74c2 annotatedProperty IAO_0000115 @default.
- Bf3457b8e1b2c4047a2b6fb88283d74c2 annotatedSource NCIT_C76890 @default.
- Bf3457b8e1b2c4047a2b6fb88283d74c2 annotatedTarget "An orally available, long-acting inhibitor of phosphodiesterase (PDE) type 4 (PDE4), with anti-inflammatory and potential antineoplastic activities. Upon administration, roflumilast and its active metabolite roflumilast N-oxide selectively and competitively bind to and inhibit PDE4, which leads to an increase of both intracellular levels of cyclic-3',5'-adenosine monophosphate (cAMP) and cAMP-mediated signaling. cAMP prevents phosphorylation of spleen tyrosine kinase (SYK) and abrogates activation of the PI3K/AKT/mTOR signaling pathway, which may result in the induction of apoptosis. PDE4, a member of the PDE superfamily that hydrolyses cAMP and 3',5'-cyclic guanosine monophosphate (cGMP) to their inactive 5' monophosphates, is upregulated in a variety of cancers and may contribute to chemoresistance; it also plays a key role in inflammation, especially in inflammatory airway diseases." @default.